Additionally, miR-146a promotes NF-kB signaling in oral, cervical, breast, and prostate cancers through the targeting of IRAK1 and TRAF6 [30,46,61], and it enhances cell growth and proliferative signaling in several cancers—including breast, liver, lung, prostate, and gastric—by targeting EGFR [30]. Here, TRAF6 is linked to cancer.